IDO1 and neoplasm: In a study in 2011, 82 patients with unresectable stage III/IV melanomas treated with ipilimumab showed, that at baseline, only positive immunostaining for the markers IDO and FOXP3 in resected tumor biopsies, could significantly distinguish patients who obtained clinical benefit from those who did not (139).